




Horizon 2020 Societal Challenge Health Funding Opportunities in Personalized Health

Ms Sasha Hugentobler, PhD., NCP Health,
Demographic change and well being

Ms Agnes Szeberenyi, Scientific Collaborator Health
Euresearch Head Office
health@euresearch.ch
+41 31 380 60 00

Personalized Health in Horizon 2020



As from 1 January 2017 Switzerland is associated to the entire Horizon 2020

Political goals of the Societal Challenges in Horizon2020

- Tackle global and societal challenges & concerns of citizens & society
- Inter-sectorial and multidisciplinary collaborative research & innovation



Basic Rules

- Problems/challenges to target were identified
- EC together with different experts prepares and launches a call with a work programme
- Work programme defines “topics”, to which solutions are thought
- You provide together with your international consortium of experts the best solution to the identified problem
- One can only submit a proposal to a topic in an open call



2018–2020 Health programme: 3 calls

The call “Better Health and care, economic growth and sustainable health systems” will be implemented through 5 priorities:

- **Personalised medicine**
- Innovative health and care industry
- Infectious diseases and improving global health
- Innovative health and care systems – Integration of care
- Decoding the role of the environment for health and well-being

Personalised medicine in H2020

- Definition used: **A medical approach which is tailored to the patient or a group of patients – for prevention, prediction and treatment**
- Areas of application include chronic, rare and communicable disease
- Type of population can including children, the ageing population or high-risk group
- Expected key impacts: Improved health outcomes for the citizens
- **The International Consortium on Personalised Medicine** will be instrumental to support these aims (no Swiss representation – yet)

Understanding call topics and how to read them

Example from WP 2018–2020

- Call topic: *Digital diagnostics – developing tools for clinical decisions integrating in vitro and in vivo diagnostics*
- Publication date: **tbd** and deadline: **tbd**
- Type of action: RIA
- **Topic description**
- Scope
 - Develop tools to support clinical decisions that will use information from the most relevant diagnostic means in a particular area.
 - Integrate in vitro and in vivo diagnostics as appropriate taking into account the needs of healthcare practitioners.
 - Proposals should be aligned with the objectives of the International Consortium for **Personalised Medicine**.
- Expected impact
 - Improve the quality and sustainability of healthcare through more encompassing diagnosis and **personalised treatments**.

Overview of funding schemes

Funding scheme/ type of action	Definition	Funding rate	Duration (in months)	Condition
Research and innovation action – RIA	Basic and applied research, technology development and integration, testing and validation on a small scale prototype in a laboratory or simulated environment	100%	36–48	≥ 3 legal entities (in AS or MS)
Innovation action – IA	produce plans and arrangements or designs for new, altered or improved products, processes or services	70% – for profit 100% – not for profit	30–36	≥ 3 legal entities (in AS or MS)
Coordination and support action – CSA	accompanying measures such dissemination, awareness raising, networking, policy dialogues, standardization	100%	12–48	1 legal entity (in AS or MS)

Overview of funding schemes II.

Funding scheme	Definition	Funding	Duration (in months)	Condition
SME instrument	<p>Φ1: making a feasibility study for an innovation idea, (i.e. 'business plan' for new, altered or improved product, process or service)</p> <p>Φ2: implementing an innovation project (incl. prototyping, testing, demonstrating, piloting, large-scale product validation and market replication)</p> <p>Φ3: support to commercial exploitation</p>	<p>Φ1: lump sum of 50kEUR</p> <p>Φ2: 0.5– 5 mio EUR</p> <p>Φ3: no funding</p>	<p>Φ1: 6</p> <p>Φ2: 12–24</p> <p>Φ3: Cont'd</p>	One for profit
Pre-commercial procurement – PCP	public procurement of R&D services and related additional coordination and networking activities	90%	18–48	≥ 3 legal entities (in MS or AS) of which 2 must be public procurers
Public procurement of innovative solutions – PPI	public procurement of innovative solutions and related additional coordination and networking activities	35%	18–48	≥ 3 legal entities (in MS or AS) of which 2 must be public procurers
Prizes	Recognize past achievements; induce future activities	1 millio EUR	variable	1 legal entity (MS or AS)

Overview of funding schemes II.

Funding scheme	Definition	Funding	Duration (in months)	Condition
ERA Net Co-fund	Coordinate research efforts of participating Member States or Associated Countries in the field described & implement joint transnational call for proposals with EU co-funding	33%	Variable	≥ 3 legal entities from 3 Member States or Associated Countries Participants must be 'research funders', i.e. legal entities owning or managing public research and innovation programmes, e.g. SNSF
European Joint Programme (EJP) Cofund actions	Support coordinated national research and innovation programmes	70%	variable	≥ 5 legal entities from 5 Member States or Associated Countries. Participants must be legal entities owning or mandated to manage national research and innovation programmes.

**Some Upcoming
Personalized Health
Topics in Call
2018-2020**



What is the next step?



Euresearch Service



What is the next step?

- Check on & subscribe to e-Alerts: www.euresearch.ch/health
- Contact us if you wish to know more about a call or topic!
- Start building a consortium




- **Open Info Day Brussels 2017– 8 December 2017**
 - Official launch of the Health Work Programme 2018–2020
- **Brokerage event Brussels organized by HNN2.0 – 7 December 2017– Partnering, creating consortia**
- **Applicant training by Euresearch in Zürich on 14 December 2017**

<https://www.euresearch.ch/en/events/event-detail/showUid/642/>

Who is Euresearch?



Head Office & Regional Offices



10 Regional Offices: Generalists, Admin, Legal & Financial support
Head Office (Bern): Specialists, Scientific & Strategic support, NCPs
SwissCore (Brussels): Lobbyist, Brussels contacts & meeting space

Health National Contact Points (NCP) are:

- Nominated by their governments
- Mandated to:
 1. Spread awareness,
 2. Provide specialist advice and guidance on Health research funding opportunities within Horizon 2020,
 3. Ensure that the programme is readily accessible to all potential applicants.

HEAD OFFICE

Euresearch
 Effingerstrasse 19
 CH-3008 Bern

 info@euresearch.ch
 +41 31 380 60 00

PARTNER

SwissCore
 Brussels, Belgium
 www.swisscore.org

HELPLINE

+41 848 499 499

www.euresearch.ch

REGIONAL OFFICES

BASEL
 BL, BS, SO
 basel@euresearch.ch
 +41 61 207 12 37

FRIBOURG
 FR, VS
 fribourg@euresearch.ch
 +41 26 300 73 30

LAUSANNE
 VD
 lausanne@euresearch.ch
 +41 21 693 47 50 / 35 70

LUCERNE
 LU, UR, SZ, OW, NW, ZG
 luzern@euresearch.ch
 +41 41 248 62 20 / 12

ST. GALLEN
 SG, AI, AR, GR, TG
 stgallen@euresearch.ch
 +41 71 224 25 28 / 29

BERN
 BE
 bern@euresearch.ch
 +41 31 631 52 72

GENEVA
 GE
 geneve@euresearch.ch
 +41 22 379 75 60

LUGANO
 TI
 lugano@euresearch.ch
 +41 58 666 45 22

NEUCHÂTEL
 NE, JU
 neuchatel@euresearch.ch
 +41 32 718 10 33 / 35

ZURICH
 ZH, AG, GL, SH
 zurich@euresearch.ch
 +41 44 634 53 50

Contact Data

Sasha Hugentobler

National contact point (NCP) Health

health@euresearch.ch

031 380 60 06

Agnes Szeberenyi

Scientific Collaborator Health

health@euresearch.ch

031 380 60 25

